- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Radiologix slides in 2Q
Service fees fell 9.1% in the second quarter for Radiologix, a national provider of diagnostic imaging services, to $65 million versus $71.5 million for the second quarter ended June 30. The drop was due primarily to reduced patient volume related to
Service fees fell 9.1% in the second quarter for Radiologix, a national provider of diagnostic imaging services, to $65 million versus $71.5 million for the second quarter ended June 30. The drop was due primarily to reduced patient volume related to increased competition in key markets. The numbers were up about 1%, however, compared with the previous quarter, during which Radiologix generated $64.4 million in service fees. The company achieved net income of $276,000 for the second quarter of 2003, compared with net income of $4.8 million for the previous year period and a net loss of $4.6 million for first quarter 2003. Company executives view the sequential improvement as evidence of stabilization in Radiologix' core business. Net income improved partly as a result of cost-cutting measures.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
